問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Dermatology

Taipei Medical University Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

李婉若Lee, Woan-Ruoh
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

List

30Cases

2019-04-15 - 2027-12-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Olumiant

Participate Sites
7Sites

Recruiting7Sites

2019-06-15 - 2025-05-31

Phase III

Completed
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3

  • Condition/Disease

    Plaque Psoriasis

  • Test Drug

    Mirikizumab

Participate Sites
7Sites

Terminated7Sites

2018-04-24 - 2020-01-16

Phase III

Completed
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1

  • Condition/Disease

    Moderate-to-Severe Plaque Psoriasis

  • Test Drug

    Mirikizumab

Participate Sites
7Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2021-04-30 - 2025-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-09-01 - 2024-07-12

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2011-02-01 - 2013-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-01-01 - 2012-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2018-08-31 - 2025-06-30

Phase III

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Upadacitinib

Participate Sites
4Sites

Terminated4Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2016-08-31 - 2018-12-31

Phase II

Multi-center, randomized, vehicle-controlled, investigator-blinded, parallel groups study to evaluate the efficacy and safety of NP000888 in subjects with plaque and nail psoriasis

  • Condition/Disease

    Psoriasis or nail psoriasis

  • Test Drug

    NP000888

Participate Sites
11Sites

Terminated11Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2021-09-01 - 2023-07-31

Phase II

Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis

  • Condition/Disease

    Prurigo Nodularis/Pruritis

  • Test Drug

    KPL-716/ vixarelimab

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB